Noe, Katherine

Association of Outpatient Follow-up with 30-day Readmission after Epilepsy or Seizure Discharge in Medicare Beneficiaries Aged 65 and Older Blank LJ, Van Hyfte G, Agarwal P, Mazumdar M, Jette J. Neurology . 2025;104(10):e213638. Background and Objectives: Older adults are expected to have higher readmission rates after seizure-related hospitalization. We sought to define the 30-day readmission rate for older adults after seizure hospitalization and to examine whether occurrence, timing, or specialization of follow-up with primary or neuro-related care is associated with lower readmission risk. Methods: This is a retrospective cohort study using 2016–2019 Medicare claims data, including adults aged older than 65 years hospitalized with a primary diagnosis of seizure/epilepsy. The primary outcome was readmission within 30 days. Exposure of interest was presence or absence of follow-up and specialty of the follow-up provider. Beneficiaries were followed from 90 days before admission to 30 days after discharge. We defined variables a priori based on literature/clinical judgment and used a least absolute shrinkage and selection operator (LASSO) method to determine factors that were contributing to the data's variance for inclusion in the final model. Results: Of 80,620 beneficiaries with admissions for seizure/epilepsy, 17.72% were readmitted within 30 days. Overall, 20.6% saw only primary care, 2.5% neurology only, 0.3% neurosurgery only, and 0.1% epilepsy only, and 5.4% had a combination of visits. Readmission rates differed by follow-up visit status: 22% readmission rate for those with no follow-up and only 6% with any health care visit. Among those with a visit, the readmission rates by specialty were as follows: 8% for primary care alone, 5% for neurology alone, 16% for neurosurgery alone, 1% for epileptology alone, and 2% for those who had seen a combination of these specialties. In our LASSO-selected multivariable model, outpatient follow-up was associated with lower odds of readmission: early (days 1–15) primary care visit (adjusted odds ratio [aOR] 0.49; 95% CI 0.45–0.52, p < .001); early neurology visit (aOR 0.39; 95% CI 0.33–0.46, p < .001); and later (days 16–30) neurosurgery visit (aOR 0.42; 95% CI 0.27–0.67, p < .001), later neurology visit (aOR 0.16; 95% CI 0.13–0.21, p < .001), or later primary care visit (aOR 0.16; 95% CI 0.14–0.17, p < .001), all associated with reduced odds of readmission. Discussion: We found high rates of readmission in older adults. Outpatient follow-up was associated with reduced odds of readmission. These findings reinforce the importance of discharge planning and suggest that ensuring outpatient follow-up with either primary care or neurology may be an easy intervention to reduce readmissions.

Risk of Perinatal and Maternal Morbidity and Mortality Among Pregnant Women With Epilepsy Razaz N, Igland J, Bjørk MH, Joseph KS, Dreier JW, Gilhus NE, Gissler M, Leinonen MK, Zoega H, Alvestad S, Christensen J, Tomson T. JAMA Neurol . 2024;81(9):985-995. Importance: Maternal epilepsy is associated with adverse pregnancy and neonatal outcomes. A better understanding of this condition and the associated risk of mortality and morbidity at the time of delivery could help reduce adverse outcomes. Objective: To determine the risk of severe maternal and perinatal morbidity and mortality among women with epilepsy. Design, Setting, Participants: This prospective population-based register study in Denmark, Finland, Iceland, Norway, and Sweden took place between January 1, 1996 and December 31, 2017. Data analysis was performed from August 2022 to November 2023. Participants included all singleton births at 22 weeks’ gestation or longer. Births with missing or invalid information on birth weight or gestational length were excluded. The study team identified 4 511 267 deliveries, of which 4 475 984 were to women without epilepsy and 35 283 to mothers with epilepsy. Exposure: Maternal epilepsy diagnosis recorded before childbirth. Prenatal exposure to antiseizure medication (ASM), defined as any maternal prescription filled from conception to childbirth, was also examined. Main Outcomes and Measures: Composite severe maternal morbidity and mortality occurring in pregnancy or within 42 days’ postpartum and composite severe neonatal morbidity (eg, neonatal convulsions) and perinatal mortality (ie, stillbirths and deaths) during the first 28 days of life. Multivariable generalized estimating equations with logit link were used to obtain adjusted odds ratio (aOR) and 95% confidence interval (CI). Results: The mean (SD) age at delivery for women in the epilepsy cohort was 29.9 (5.3) years. The rate of composite severe maternal morbidity and mortality was also higher in women with epilepsy compared with those without epilepsy (36.9 vs 25.4 per 1000 deliveries). Women with epilepsy also had a significantly higher risk of death (0.23 deaths per 1000 deliveries) compared with women without epilepsy (0.05 deaths per 1000 deliveries) with an aOR of 3.86 (95% CI, 1.48-8.10). In particular, maternal epilepsy was associated with increased odds of severe preeclampsia, embolism, disseminated intravascular coagulation or shock, cerebrovascular events, and severe mental health conditions. Fetuses and infants of women with epilepsy were at elevated odds of mortality (aOR, 1.20; 95% CI, 1.05-1.38) and severe neonatal morbidity (aOR, 1.48; 95% CI, 1.40-1.56). In analyses restricted to women with epilepsy, women exposed to ASM compared with those unexposed had higher odds of severe maternal morbidity (aOR, 1.24; 95% CI, 1.10-1.48) and their neonates had an increased odd of mortality and severe morbidity (aOR, 1.37; 95% CI, 1.23-1.52). Conclusion and Relevance: This multinational study shows that women with epilepsy were at considerably higher risk of severe maternal and perinatal outcomes and increased risk of death during pregnancy and postpartum. Maternal epilepsy and maternal use of ASM were associated with increased maternal morbidity and perinatal mortality and morbidity.